On June 13th, Glon Hui reported that Pfizer (PFE.US) fell 1.1% to $27.355. Pfizer announced that its gene therapy for Duchenne muscular dystrophy (DMD) failed to meet primary and secondary endpoints in late-stage clinical trials for young boys. Although Pfizer did not disclose specific trial data, it said that in secondary endpoints such as 10-meter walking or running speed and time to rise from the floor indicators, the group receiving gene therapy did not show a significant difference compared to the placebo group.
美股异动｜辉瑞跌1.1% 杜氏肌营养不良症基因疗法晚期临床试验宣告失败
US Stocks Change: Pfizer drops by 1.1% due to the late-stage clinical trial failure of DMD gene therapy by Duchenne muscular dystrophy.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.